This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Effect of R-spondin3 on Sepsis Induced Endothelial Dysfunction

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

About this trial

Last updated 5 years ago

Study ID

XHEC-C-2020-084

Status

Unknown status

Type

Observational

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Trial Timing

Ended 4 years ago

What is this trial about?

Sepsis is the most frequent risk factor for ALI/ARDS. Meanwhile, Pulmonary is the most vulnerable organ to fail in response to sepsis, vascular endothelial dysfunction is a central event in the pathophysiology of sepsis. An improved understanding of endothelial response and associated biomarkers may lead to strategies to more accurately predict outcome and develop novel endothelium-directed therapies in sepsis. The human and mouse R-spondins encode a family of proteins that includes four paralogs (R-spo1-4). R-spondins are secreted proteins found primarily in the extracellular region and are known to promote β-catenin signaling. Among them, the embryonic lethal vascular remodeling phenotype of R-spondin3 (Rspo3) mutant mice suggests a role of EC derived Rspo3 in angiogenesis. Rspo3 protects tissues against mesenteric I/R by tightening endothelial cell junction and improving vascular intergrity. However, the role of Rspo3 in sepsis-induced pulmonary endothelial dysfunction remains unclear. Thus, it is worthwhile to explore the relationship between Rspo3 and sepsis-induced lung injury, which will be helpful for prevention and treatment of sepsis-induced lung injury and endothelial dysfunction.

What are the participation requirements?

Yes

Inclusion Criteria

- patients with sepsis defined as SIRS combined with an infectious episode and dysfunction of one or more organ

- age older than 18 years SIRS is considered to be present when patients have more than one of the following clinical findings:

- Body temperature higher than 38°C or lower than 36°C;

- Heart rate higher than 90/min

- Hyperventilation evidenced by respiratory rate higher than 20/min or PaCO2 lower than 32 mmHg;

- White blood cell count higher than 12,000 cells/ µl or lower than 4,000/ µl.

No

Exclusion Criteria

- patients younger than 18

- women during pregnancy or lactation; being involved in other clinical subjects.

Locations

Location

Status

Recruiting